OliX PharmaceuticalsInc (226950 KQ) stock market data APIs
₩38461.9596
489(1.3%)
as of July 2, 2025
Try our APIs with
free plan!
OliX PharmaceuticalsInc Financial Data Overview
Price chart is built with
Anychart
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
Prev. Close
38461.9596
Open
38950.9599
High
40334.4615
Low
37611.4582
52 wk Range
8790-64000
Market Cap
711 618 M
Shares Outstanding
18 460 K
Revenue
5 885 M
EPS
-708.8354
Beta
0.828
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OliX PharmaceuticalsInc data using free add-ons & libraries
Get OliX PharmaceuticalsInc Fundamental Data
OliX PharmaceuticalsInc Fundamental data includes:
- Net Revenue: 5 885 M
- EBITDA: -26 453 331 968
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OliX PharmaceuticalsInc News
New
OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease
SUWON, South Korea, June 15, 2022—(BUSINESS WIRE)—OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. ha...
OliX Pharmaceuticals to Conduct Business Meetings with Potential Partners at 2022 BIO International Convention
SUWON, South Korea, June 09, 2022—(BUSINESS WIRE)—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will partic...
OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars
SUWON, South Korea, June 03, 2022—(BUSINESS WIRE)—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the completion of patient enrollment in the...
OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvement
SUWON, South Korea, May 25, 2022—(BUSINESS WIRE)—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has successfully completed a capi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
